110 related articles for article (PubMed ID: 32229417)
21. Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer.
Dall'Era MA; Lo MJ; Chen J; Cress R; Hamilton AS
Cancer; 2018 May; 124(9):1921-1928. PubMed ID: 29499075
[TBL] [Abstract][Full Text] [Related]
22. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer mortality in the Finnish randomized screening trial.
Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
[TBL] [Abstract][Full Text] [Related]
24. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.
Akre O; Garmo H; Adolfsson J; Lambe M; Bratt O; Stattin P
Eur Urol; 2011 Sep; 60(3):554-63. PubMed ID: 21664039
[TBL] [Abstract][Full Text] [Related]
25. Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer.
Thomsen FB; Røder MA; Jakobsen H; Langkilde NC; Borre M; Jakobsen EB; Frey A; Lund L; Lunden D; Dahl C; Brasso K
Clin Genitourin Cancer; 2019 Aug; 17(4):e814-e821. PubMed ID: 31196798
[TBL] [Abstract][Full Text] [Related]
26. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Haring A; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
Scand J Urol; 2017 Feb; 51(1):5-12. PubMed ID: 28084175
[TBL] [Abstract][Full Text] [Related]
27. Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use.
Sarre S; Määttänen L; Tammela TL; Auvinen A; Murtola TJ
Scand J Urol; 2016 Aug; 50(4):267-73. PubMed ID: 26927237
[TBL] [Abstract][Full Text] [Related]
28. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
Loeb S; Zhu X; Schroder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
[TBL] [Abstract][Full Text] [Related]
29. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
[TBL] [Abstract][Full Text] [Related]
30. Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011.
Evans SM; Millar JL; Davis ID; Murphy DG; Bolton DM; Giles GG; Frydenberg M; Andrianopoulos N; Wood JM; Frauman AG; Costello AJ; McNeil JJ
Med J Aust; 2013 Jun; 198(10):540-5. PubMed ID: 23725268
[TBL] [Abstract][Full Text] [Related]
31. Impact of patient educational level on treatment for patients with prostate cancer: data from CaPSURE.
Kane CJ; Lubeck DP; Knight SJ; Spitalny M; Downs TM; Grossfeld GD; Pasta DJ; Mehta SS; Carroll PR
Urology; 2003 Dec; 62(6):1035-9. PubMed ID: 14665350
[TBL] [Abstract][Full Text] [Related]
32. Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer.
Vetterlein MW; Löppenberg B; Karabon P; Dalela D; Jindal T; Sood A; Chun FK; Trinh QD; Menon M; Abdollah F
Cancer; 2017 Sep; 123(17):3241-3252. PubMed ID: 28472547
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
34. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
[TBL] [Abstract][Full Text] [Related]
35. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
36. Allopurinol and prostate cancer survival in a Finnish population-based cohort.
Kukko V; Kaipia A; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
Prostate Cancer Prostatic Dis; 2024 Mar; 27(1):73-80. PubMed ID: 36131010
[TBL] [Abstract][Full Text] [Related]
37. Risk of subsequent primary cancers after carbon ion radiotherapy, photon radiotherapy, or surgery for localised prostate cancer: a propensity score-weighted, retrospective, cohort study.
Mohamad O; Tabuchi T; Nitta Y; Nomoto A; Sato A; Kasuya G; Makishima H; Choy H; Yamada S; Morishima T; Tsuji H; Miyashiro I; Kamada T
Lancet Oncol; 2019 May; 20(5):674-685. PubMed ID: 30885458
[TBL] [Abstract][Full Text] [Related]
38. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
[TBL] [Abstract][Full Text] [Related]
39. Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate Cancer.
Kilpeläinen TP; Mäkinen T; Karhunen PJ; Aro J; Lahtela J; Taari K; Talala K; Tammela TL; Auvinen A
Cancer Epidemiol; 2016 Dec; 45():1-5. PubMed ID: 27636505
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]